SpermaTech AS Competitors

About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 750,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ® Liquid Select™ test. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn. About Oncotype DX® The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score®, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score™ predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score™ predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 750,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.

ReproTech is committed to maintaining the highest level of expertise in the reproductive tissue banking industry by ensuring the safety and accuracy of the tissues entrusted to us. Our rigorous quality controls ensure that shipments are safe and efficient, and we believe in the highest standards of safe storage for our clients' cryopreserved reproductive tissues which include frequent manual tank inspections and sophisticated 24/7 monitoring systems and analysis. We are dedicated to assisting our clinical partners with regulatory compliance in the areas of tissue storage, donor gametes, and donor embryos.

Embryotech Laboratories is an ISO-17025 accredited test laboratory providing services to the assisted reproductive technologies industry and laboratories, providing the latest quality control assays including MEA (Mouse Embryo Assay) that is used for toxicity and functionality testing of raw materials, media, labware, disposables and any device which may come into contact with gametes or embryos. Embryotech Laboratories also offers endotoxin testing via Limulus Amebocyte Lysate Assay (LAL test) utilizing: Kinetic Turbidimetric quantitative and Gel-Clot qualitative testing. The company is also a provider of several sperm assays including Sperm Motility Index and Sperm Penetration. In addition, it is the leader in supplying all stages of fresh and cryopreserved mouse embryos as well as hamster ova to clinics and universities around the world aiding in technician training and proficiency testing.